Driving transcriptional regulators in melanoma metastasis

Cancer and Metastasis Reviews

Volumn 31, Issue 3-4, 2012, Pages 621-632

  Mobley, Aaron K ^a   Braeuer, Russell R ^a   Kamiya, Takafumi ^a   Shoshan, Einav ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AP2 ; CREB; Melanoma; Metastasis; Transcription

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ACTIVATING TRANSCRIPTION FACTOR 2; CD146 ANTIGEN; CELL ADHESION MOLECULE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; IPILIMUMAB; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; PROTEIN BCL 2; PROTEIN P21; PROTEINASE ACTIVATED RECEPTOR 1; RNA; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; VASCULOTROPIN; VEMURAFENIB;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER INVASION; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; GENE EXPRESSION; GROWTH CURVE; HUMAN; IMMUNOPATHOLOGY; MELANOMA; METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RNA EDITING; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 1; ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NF-KAPPA B; RNA EDITING; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 84867985848     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-012-9358-8     Document Type: Article

References (153)

1. Siegel, R.; Naishadham, D.; & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62(1), 10-29.
2. Balch, C. M.; Gershenwald, J. E.; Soong, S. J.; Thompson, J. F.; Atkins, M. B.; Byrd, D. R.; et al. (2009). Final version of 2009 AJCC melanoma staging and classification. Jounal Clinical Oncology, 27(36), 6199-6206.
3. Clark, W. H.; Jr.; Elder, D. E.; Guerry, D. T.; Epstein, M. N.; Greene, M. H.; & Van Horn, M. (1984). A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Human Pathology, 15(12), 1147-1165.
4. Satyamoorthy, K.; & Herlyn, M. (2002). Cellular and molecular biology of human melanoma. Cancer Biology & Therapy, 1(1), 14-17.
5. Leslie, M. C.; & Bar-Eli, M. (2005). Regulation of gene expression in melanoma: new approaches for treatment. Journal Cell Biochemistry, 94(1), 25-38.
6. Greene, V. R.; Johnson, M. M.; Grimm, E. A.; & Ellerhorst, J. A. (2009). Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. Journal Investigation Dermatology, 129(6), 1483-1488.
7. Villanueva, J.; & Herlyn, M. (2008). Melanoma and the tumor microenvironment. Current Oncology Reports, 10(5), 439-446.
8. Chin, L. (2003). The genetics of malignant melanoma: Lessons from mouse and man. Nature Revista Cancer, 3(8), 559-570.
9. Gray-Schopfer, V.; Wellbrock, C.; & Marais, R. (2007). Melanoma biology and new targeted therapy. Nature, 445(7130), 851-857.
10. Leiter, U.; Meier, F.; Schittek, B.; & Garbe, C. (2004). The natural course of cutaneous melanoma. Journal Surgery Oncology, 86(4), 172-178.
11. Patel, J. K.; Didolkar, M. S.; Pickren, J. W.; & Moore, R. H. (1978). Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. The American Journal of Surgery, 135(6), 807-810.
12. Fidler, I. J. (2002). Critical determinants of metastasis. Seminars in Cancer Biology, 12(2), 89-96.
13. Williams, T.; Admon, A.; Luscher, B.; & Tjian, R. (1988). Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Developments, 2(12A), 1557-1569.
14. Gravel, M.; Gao, E.; Hervouet-Zeiber, C.; Parsons, V.; & Braun, P. E. (2000). Transcriptional regulation of 2′,3′-cyclic nucleotide 3′-phosphodiesterase gene expression by cyclic AMP in C6 cells. Journal of Neurochemistry, 75(5), 1940-1950.
15. Buettner, R.; Kannan, P.; Imhof, A.; Bauer, R.; Yim, S. O.; Glockshuber, R.; et al. (1993). An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. Molecular Cell Biology, 13(7), 4174-4185.
16. Imagawa, M.; Chiu, R.; & Karin, M. (1987). Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP. Cell, 51(2), 251-260.
17. Schorle, H.; Meier, P.; Buchert, M.; Jaenisch, R.; & Mitchell, P. J. (1996). Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature, 381(6579), 235-238.
18. Luscher, B.; Mitchell, P. J.; Williams, T.; & Tjian, R. (1989). Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Genes & Development, 3(10), 1507-1517.
19. Zhang, J.; & Williams, T. (2003). Identification and regulation of tissue-specific cis-acting elements associated with the human AP-2alpha gene. Development Dynamics, 228(2), 194-207.
20. Zeng, Y. X.; Somasundaram, K.; & el-Deiry, W. S. (1997). AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nature Genetics, 15(1), 78-82.
21. McPherson, L. A.; Loktev, A. V.; & Weigel, R. J. (2002). Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. Journal Biology Chemistry, 277(47), 45028-45033.
22. Wajapeyee, N.; & Somasundaram, K. (2003). Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. Journal Biology Chemistry, 278(52), 52093-52101.
23. Tellez, C. S.; Davis, D. W.; Prieto, V. G.; Gershenwald, J. E.; Johnson, M. M.; McCarty, M. F.; et al. (2007). Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2alpha and protease-activated receptor-1 expression during melanoma progression. Journal Investment Dermatology, 127(2), 387-393.
24. Berger, A. J.; Davis, D. W.; Tellez, C.; Prieto, V. G.; Gershenwald, J. E.; Johnson, M. M.; et al. (2005). Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Research, 65(23), 11185-11192.
25. Karjalainen, J. M.; Kellokoski, J. K.; Eskelinen, M. J.; Alhava, E. M.; & Kosma, V. M. (1998). Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. Journal of Clinical Oncology, 16(11), 3584-3591.
26. Melnikova, V. O.; Dobroff, A. S.; Zigler, M.; Villares, G. J.; Braeuer, R. R.; Wang, H.; et al. (2010). CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PloS One, 5(8), e12452.
27. Huang, S.; Jean, D.; Luca, M.; Tainsky, M. A.; & Bar-Eli, M. (1998). Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. The EMBO Journal, 17(15), 4358-4369.
28. Gershenwald, J. E.; Sumner, W.; Calderone, T.; Wang, Z.; Huang, S.; & Bar-Eli, M. (2001). Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene, 20(26), 3363-3375.
29. Tellez, C.; McCarty, M.; Ruiz, M.; & Bar-Eli, M. (2003). Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. Journal Biology Chemistry, 278(47), 46632-46642.
30. Jean, D.; Gershenwald, J. E.; Huang, S.; Luca, M.; Hudson, M. J.; Tainsky, M. A.; et al. (1998). Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. Journal Biology Chemistry, 273(26), 16501-16508.
31. Bar-Eli, M. (1997). Molecular mechanisms of melanoma metastasis. Journal Cell Physiology, 173(2), 275-278.
32. Ruiz, M.; Pettaway, C.; Song, R.; Stoeltzing, O.; Ellis, L.; & Bar-Eli, M. (2004). Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Research, 64(2), 631-638.
33. Lassam, N.; & Bickford, S. (1992). Loss of c-kit expression in cultured melanoma cells. Oncogene, 7(1), 51-56.
34. Yamamoto, K.; Tojo, A.; Aoki, N.; & Shibuya, M. (1993). Characterization of the promoter region of the human c-kit proto-oncogene. Japan Journal Cancer Research, 84(11), 1136-1144.
35. Pacifico, M. D.; Grover, R.; Richman, P. I.; Daley, F. M.; Buffa, F.; & Wilson, G. D. (2005). Development of a tissue array for primary melanoma with long-term follow-up: Discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstruction Surgery, 115(2), 367-375.
36. Shih, I. M.; Elder, D. E.; Speicher, D.; Johnson, J. P.; & Herlyn, M. (1994). Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Research, 54(9), 2514-2520.
37. Ellis, H. A.; & Peart, K. M. (1976). Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis. Journal of Clinical Pathology, 29(6), 502-516.
38. Xie, S.; Luca, M.; Huang, S.; Gutman, M.; Reich, R.; Johnson, J. P.; et al. (1997). Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Research, 57(11), 2295-2303.
39. Natali, P. G.; Nicotra, M. R.; Digiesi, G.; Cavaliere, R.; Bigotti, A.; Trizio, D.; et al. (1994). Expression of gp185HER-2 in human cutaneous melanoma: Implications for experimental immunotherapeutics. International Journal of Cancer, 56(3), 341-346.
40. Melnikova, V. O.; Villares, G. J.; & Bar-Eli, M. (2008). Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenvironment, 1(1), 103-111.
41. Fischer, E. G.; Ruf, W.; & Mueller, B. M. (1995). Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Research, 55(8), 1629-1632.
42. Vu, T. K.; Hung, D. T.; Wheaton, V. I.; & Coughlin, S. R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell, 64(6), 1057-1068.
43. Macfarlane, S. R.; Seatter, M. J.; Kanke, T.; Hunter, G. D.; & Plevin, R. (2001). Proteinase-activated receptors. Pharmacology Review, 53(2), 245-282.
44. Grand, R. J.; Turnell, A. S.; & Grabham, P. W. (1996). Cellular consequences of thrombin-receptor activation. Biochemistry Journal, 313(Pt 2), 353-368.
45. Villares, G. J.; Zigler, M.; Wang, H.; Melnikova, V. O.; Wu, H.; Friedman, R.; et al. (2008). Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Research, 68(21), 9078-9086.
46. Zucker, S.; Conner, C.; DiMassmo, B. I.; Ende, H.; Drews, M.; Seiki, M.; et al. (1995). Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. Journal Biology Chemistry, 270(40), 23730-23738.
47. Yoshida, E.; Verrusio, E. N.; Mihara, H.; Oh, D.; & Kwaan, H. C. (1994). Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Research, 54(12), 3300-3304.
48. Melnikova, V. O.; Balasubramanian, K.; Villares, G. J.; Dobroff, A. S.; Zigler, M.; Wang, H.; et al. (2009). Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. Journal Biology Chemistry, 284(42), 28845-28855.
49. Im, S. Y.; Ko, H. M.; Kim, J. W.; Lee, H. K.; Ha, T. Y.; Lee, H. B.; et al. (1996). Augmentation of tumor metastasis by platelet-activating factor. Cancer Research, 56(11), 2662-2665.
50. Melnikova, V. O.; Mourad-Zeidan, A. A.; Lev, D. C.; & Bar-Eli, M. (2006). Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. Journal Biology Chemistry, 281(5), 2911-2922.
51. Axelrad, T. W.; Deo, D. D.; Ottino, P.; Van Kirk, J.; Bazan, N. G.; Bazan, H. E.; et al. (2004). Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. The FASEB Journal, 18(3), 568-570.
52. Villares, G. J.; Dobroff, A. S.; Wang, H.; Zigler, M.; Melnikova, V. O.; Huang, L.; et al. (2009). Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Research, 69(16), 6730-6737.
53. Pollmann, M. A.; Shao, Q.; Laird, D. W.; & Sandig, M. (2005). Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture. Breast Cancer Research, 7(4), R522-R534.
54. el-Sabban, M. E.; & Pauli, B. U. (1994). Adhesion-mediated gap junctional communication between lung-metastatatic cancer cells and endothelium. Invasion & Metastasis, 14(1-6), 164-176.
55. Villares, G. J.; Zigler, M.; Dobroff, A. S.; Wang, H.; Song, R.; Melnikova, V. O.; et al. (2011). Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Processes National Academy Science U S A, 108(2), 626-631.
56. Bohm, M.; Moellmann, G.; Cheng, E.; Alvarez-Franco, M.; Wagner, S.; Sassone-Corsi, P.; et al. (1995). Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differences, 6(3), 291-302.
57. Rutberg, S. E.; Goldstein, I. M.; Yang, Y. M.; Stackpole, C. W.; & Ronai, Z. (1994). Expression and transcriptional activity of AP-1, CRE, and URE binding proteins in B16 mouse melanoma subclones. Molecular Carcinogenesis, 10(2), 82-87.
58. Ravnskjaer, K.; Kester, H.; Liu, Y.; Zhang, X.; Lee, D.; Yates, J. R.; 3rd, et al. (2007). Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. The EMBO Journal, 26(12), 2880-2889.
59. Shaywitz, A. J.; & Greenberg, M. E. (1999). CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annual Review of Biochemistry, 68, 821-861.
60. Meyer, T. E.; & Habener, J. F. (1993). Cyclic adenosine 3′,5′-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocrine Review, 14(3), 269-290.
61. Mayr, B.; & Montminy, M. (2001). Transcriptional regulation by the phosphorylation-dependent factor CREB. Nature Review Molecular Cell Biology, 2(8), 599-609.
62. Iourgenko, V.; Zhang, W.; Mickanin, C.; Daly, I.; Jiang, C.; Hexham, J. M.; et al. (2003). Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Process National Academy Science U S A, 100(21), 12147-12152.
63. Montminy, M. (1997). Transcriptional regulation by cyclic AMP. Annual Review of Biochemistry, 66, 807-822.
64. Melnikova, V. O.; & Bar-Eli, M. (2008). Transcriptional control of the melanoma malignant phenotype. Cancer Biology & Therapy, 7(7), 997-1003.
65. White, P. C.; Shore, A. M.; Clement, M.; McLaren, J.; Soeiro, I.; Lam, E. W.; et al. (2006). Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene, 25(15), 2170-2180.
66. Zhang, X.; Odom, D. T.; Koo, S. H.; Conkright, M. D.; Canettieri, G.; Best, J.; et al. (2005). Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Process National Academy Science U S A, 102(12), 4459-4464.
67. Xie, S.; Price, J. E.; Luca, M.; Jean, D.; Ronai, Z.; & Bar-Eli, M. (1997). Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene, 15(17), 2069-2075.
68. Jean, D.; & Bar-Eli, M. (2000). Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Molecular Cell Biochemistry, 212(1-2), 19-28.
69. Jean, D.; & Bar-Eli, M. (2001). Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: potential modality for cancer therapy. Criticism Review Immunology, 21(1-3), 275-286.
70. Jean, D.; Tellez, C.; Huang, S.; Davis, D. W.; Bruns, C. J.; McConkey, D. J.; et al. (2000). Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene, 19(22), 2721-2730.
71. Jean, D.; Harbison, M.; McConkey, D. J.; Ronai, Z.; & Bar-Eli, M. (1998). CREB and its associated proteins act as survival factors for human melanoma cells. Journal Biology Chemistry, 273(38), 24884-24890.
72. Dobroff, A. S.; Wang, H.; Melnikova, V. O.; Villares, G. J.; Zigler, M.; Huang, L.; et al. (2009). Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. Journal Biology Chemistry, 284(38), 26194-26206.
73. Brigstock, D. R. (2003). The CCN family: A new stimulus package. The Journal of Endocrinology, 178(2), 169-175.
74. Bertolotto, C.; Abbe, P.; Hemesath, T. J.; Bille, K.; Fisher, D. E.; Ortonne, J. P.; et al. (1998). Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. The Journal of Cell Biology, 142(3), 827-835.
75. Price, E. R.; Horstmann, M. A.; Wells, A. G.; Weilbaecher, K. N.; Takemoto, C. M.; Landis, M. W.; et al. (1998). alpha-Melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome. Journal Biology Chemistry, 273(49), 33042-33047.
76. Nyormoi, O.; & Bar-Eli, M. (2003). Transcriptional regulation of metastasis-related genes in human melanoma. Clinical & Experimental Metastasis, 20(3), 251-263.
77. Zhuang, L.; Lee, C. S.; Scolyer, R. A.; McCarthy, S. W.; Zhang, X. D.; Thompson, J. F.; et al. (2007). Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology, 20(4), 416-426.
78. Fuse, N.; Yasumoto, K.; Suzuki, H.; Takahashi, K.; & Shibahara, S. (1996). Identification of a melanocyte-type promoter of the microphthalmia- associated transcription factor gene. Biochemistry Biophysics Research Communication, 219(3), 702-707.
79. Widlund, H. R.; & Fisher, D. E. (2003). Microphthalamia-associated transcription factor: A critical regulator of pigment cell development and survival. Oncogene, 22(20), 3035-3041.
80. Ganss, R.; Schutz, G.; & Beermann, F. (1994). The mouse tyrosinase gene. Promoter modulation by positive and negative regulatory elements. Journal Biology Chemistry, 269(47), 29808-29816.
81. Dorsky, R. I.; Moon, R. T.; & Raible, D. W. (1998). Control of neural crest cell fate by the Wnt signalling pathway. Nature, 396(6709), 370-373.
82. McCallion, A. S.; & Chakravarti, A. (2001). EDNRB/EDN3 and Hirschsprung disease type II. Pigments Cell Research, 14(3), 161-169.
83. Lang, D.; & Epstein, J. A. (2003). Sox10 and Pax3 physically interact to mediate activation of a conserved c-RET enhancer. Human Molecular Genetics, 12(8), 937-945.
84. King, R.; Googe, P. B.; Weilbaecher, K. N.; Mihm, M. C.; Jr.; & Fisher, D. E. (2001). Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors. American Journal Surgery Pathology, 25(1), 51-57.
85. Garraway, L. A.; Widlund, H. R.; Rubin, M. A.; Getz, G.; Berger, A. J.; Ramaswamy, S.; et al. (2005). Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 436(7047), 117-122.
86. Widlund, H. R.; Horstmann, M. A.; Price, E. R.; Cui, J.; Lessnick, S. L.; Wu, M.; et al. (2002). Beta-catenin-induced melanoma growth requires the downstream target microphthalmia-associated transcription factor. The Journal of Cell Biology, 158(6), 1079-1087.
87. Chien, A. J.; Moore, E. C.; Lonsdorf, A. S.; Kulikauskas, R. M.; Rothberg, B. G.; Berger, A. J.; et al. (2009). Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proceedings National Academy Science U S A, 106(4), 1193-1198.
88. Takeda, K.; Yasumoto, K.; Takada, R.; Takada, S.; Watanabe, K.; Udono, T.; et al. (2000). Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. Journal Biology Chemistry, 275(19), 14013-14016.
89. Asundi, J.; Reed, C.; Arca, J.; McCutcheon, K.; Ferrando, R.; Clark, S.; et al. (2011). An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma. Clin Cancer Res, 17(5), 965-975.
90. Fuchs, S.; Amiel, J.; Claudel, S.; Lyonnet, S.; Corvol, P.; & Pinet, F. (2001). Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: Evidence for selective loss of Gi coupling. Molecular Medical, 7(2), 115-124.
91. Imokawa, G.; Yada, Y.; & Kimura, M. (1996). Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes. Biochemistry Journal, 314(Pt 1), 305-312.
92. Ji, M.; & Andrisani, O. M. (2005). High-level activation of cyclic AMP signaling attenuates bone morphogenetic protein 2-induced sympathoadrenal lineage development and promotes melanogenesis in neural crest cultures. Molecular Cell Biology, 25(12), 5134-5145.
93. Busca, R.; Berra, E.; Gaggioli, C.; Khaled, M.; Bille, K.; Marchetti, B.; et al. (2005). Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. The Journal of Cell Biology, 170(1), 49-59.
94. McGill, G. G.; Horstmann, M.; Widlund, H. R.; Du, J.; Motyckova, G.; Nishimura, E. K.; et al. (2002). Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell, 109(6), 707-718.
95. Du, J.; Widlund, H. R.; Horstmann, M. A.; Ramaswamy, S.; Ross, K.; Huber, W. E.; et al. (2004). Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell, 6(6), 565-576.
96. Carreira, S.; Goodall, J.; Denat, L.; Rodriguez, M.; Nuciforo, P.; Hoek, K. S.; et al. (2006). Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes & Development, 20(24), 3426-3439.
97. Jeffs, A. R.; Glover, A. C.; Slobbe, L. J.; Wang, L.; He, S.; Hazlett, J. A.; et al. (2009). A gene expression signature of invasive potential in metastatic melanoma cells. PloS One, 4(12), e8461.
98. Cheli, Y.; Giuliano, S.; Botton, T.; Rocchi, S.; Hofman, V.; Hofman, P.; et al. (2011). Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene, 30(20), 2307-2318.
99. Cheli, Y.; Giuliano, S.; Fenouille, N.; Allegra, M.; Hofman, V.; Hofman, P.; et al. (2012). Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene, 31, 2461-2470.
100. Hai, T. W.; Liu, F.; Coukos, W. J.; & Green, M. R. (1989). Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes & Development, 3(12B), 2083-2090.
101. Bhoumik, A.; Huang, T. G.; Ivanov, V.; Gangi, L.; Qiao, R. F.; Woo, S. L.; et al. (2002). An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis. Journal Clinical Investment, 110(5), 643-650.
102. Kaszubska, W.; Hooft van Huijsduijnen, R.; Ghersa, P.; DeRaemy-Schenk, A. M.; Chen, B. P.; Hai, T.; et al. (1993). Cyclic AMP-independent ATF family members interact with NF-kappa B and function in the activation of the E-selectin promoter in response to cytokines. Molecular Cell Biology, 13(11), 7180-7190.
103. Berger, A. J.; Kluger, H. M.; Li, N.; Kielhorn, E.; Halaban, R.; Ronai, Z.; et al. (2003). Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Research, 63(23), 8103-8107.
104. Gupta, S.; Campbell, D.; Derijard, B.; & Davis, R. J. (1995). Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science, 267(5196), 389-393.
105. Kim, S. J.; Wagner, S.; Liu, F.; O'Reilly, M. A.; Robbins, P. D.; & Green, M. R. (1992). Retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature, 358(6384), 331-334.
106. Shimizu, M.; Nomura, Y.; Suzuki, H.; Ichikawa, E.; Takeuchi, A.; Suzuki, M.; et al. (1998). Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4. Experimental Cell Research, 239(1), 93-103.
107. Tsai, E. Y.; Jain, J.; Pesavento, P. A.; Rao, A.; & Goldfeld, A. E. (1996). Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Molecular Cell Biology, 16(2), 459-467.
108. Gould Rothberg, B. E.; Berger, A. J.; Molinaro, A. M.; Subtil, A.; Krauthammer, M. O.; Camp, R. L.; et al. (2009). Melanoma prognostic model using tissue microarrays and genetic algorithms. Journal of Clinical Oncology, 27(34), 5772-5780.
109. Lau, E.; Kluger, H.; Varsano, T.; Lee, K.; Scheffler, I.; Rimm, D. L.; et al. (2012) PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell, 148(3), 543-555.
110. Shah, M.; Bhoumik, A.; Goel, V.; Dewing, A.; Breitwieser, W.; Kluger, H.; et al. (2010). A role for ATF2 in regulating MITF and melanoma development. PLoS Genet, 6(12), e1001258.
111. Perkins, N. D. (2012). The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer, 12(2), 121-132.
112. Karin, M.; & Greten, F. R. (2005). NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nature Review Immunology, 5(10), 749-759.
113. Prakash, M.; Kale, S.; Ghosh, I.; Kundu, G. C.; & Datta, K. (2011). Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-kappa B dependent MMP-2 activation through integrin alpha(v)beta(3) interaction. Cell Signal, 23(10), 1563-1577.
114. Persad, S.; & Dedhar, S. (2003). The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Review, 22(4), 375-384.
115. Wani, A. A.; Jafarnejad, S. M.; Zhou, J.; & Li, G. (2011). Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappaB/interleukin-6 signaling pathway. Oncogene, 30(24), 2778-2788.
116. Feng, Y.; Barile, E.; De, S. K.; Stebbins, J. L.; Cortez, A.; Aza-Blanc, P.; et al. (2011) Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-kappaB pathways. Pigment Cell Melanoma Res, 24(4), 703-713.
117. Amschler, K.; Schon, M. P.; Pletz, N.; Wallbrecht, K.; Erpenbeck, L.; & Schon, M. (2010) NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. J Invest Dermatol, 130(4), 1073-1086.
118. Brennecke, J.; Stark, A.; Russell, R. B.; & Cohen, S. M. (2005). Principles of microRNA-target recognition. PLoS Biology, 3(3), e85.
119. Lee, R. C.; Feinbaum, R. L.; & Ambros, V. (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 843-854.
120. Wightman, B.; Ha, I.; & Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75(5), 855-862.
121. Krol, J.; Loedige, I.; & Filipowicz, W. (2010). The widespread regulation of microRNA biogenesis, function and decay. Nature Reviews Genetics, 11(9), 597-610.
122. Mueller, D. W.; & Bosserhoff, A. K. (2009). Role of miRNAs in the progression of malignant melanoma. British Journal of Cancer, 101(4), 551-556.
123. Griffiths-Jones, S.; Saini, H. K.; van Dongen, S.; & Enright, A. J. (2008). miRBase: tools for microRNA genomics. Nucleic Acids Research, 36(Database issue), D154-D158.
124. Lu, J.; Getz, G.; Miska, E. A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834-838.
125. Gaur, A.; Jewell, D. A.; Liang, Y.; Ridzon, D.; Moore, J. H.; Chen, C.; et al. (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Research, 67(6), 2456-2468.
126. Blower, P. E.; Verducci, J. S.; Lin, S.; Zhou, J.; Chung, J. H.; Dai, Z.; et al. (2007). MicroRNA expression profiles for the NCI-60 cancer cell panel. Molecular Cancer Therapy, 6(5), 1483-1491.
127. Mueller, D. W.; Rehli, M.; & Bosserhoff, A. K. (2009). miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. Journal Investment Dermatology, 129(7), 1740-1751.
128. Haflidadottir, B. S.; Bergsteinsdottir, K.; Praetorius, C.; & Steingrimsson, E. (2010). miR-148 regulates Mitf in melanoma cells. PLoS One, 5(7), e11574.
129. Bemis, L. T.; Chen, R.; Amato, C. M.; Classen, E. H.; Robinson, S. E.; Coffey, D. G.; et al. (2008). MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Research, 68(5), 1362-1368.
130. Segura, M. F.; Hanniford, D.; Menendez, S.; Reavie, L.; Zou, X.; Alvarez-Diaz, S.; et al. (2009). Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proceeding National Academy Science U S A, 106(6), 1814-1819.
131. Felicetti, F.; Errico, M. C.; Bottero, L.; Segnalini, P.; Stoppacciaro, A.; Biffoni, M.; et al. (2008). The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Research, 68(8), 2745-2754.
132. Chen, J.; Feilotter, H. E.; Pare, G. C.; Zhang, X.; Pemberton, J. G.; Garady, C.; et al. (2010). MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. American Journal of Pathology, 176(5), 2520-2529.
133. Kitago, M.; Martinez, S. R.; Nakamura, T.; Sim, M. S.; & Hoon, D. S. (2009). Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clinical Cancer Research, 15(9), 2988-2994.
134. Muller, D. W.; & Bosserhoff, A. K. (2008). Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene, 27(52), 6698-6706.
135. Schultz, J.; Lorenz, P.; Gross, G.; Ibrahim, S.; & Kunz, M. (2008). MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Research, 18(5), 549-557.
136. Bar-Eli, M. (2011). Searching for the 'melano-miRs': miR-214 drives melanoma metastasis. The EMBO Journal, 30(10), 1880-1881.
137. Penna, E.; Orso, F.; Cimino, D.; Tenaglia, E.; Lembo, A.; Quaglino, E.; et al. (2011). microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. The EMBO Journal, 30(10), 1990-2007.
138. Keegan, L. P.; Gallo, A.; & O'Connell, M. A. (2001). The many roles of an RNA editor. Nature Review Genet, 2(11), 869-878.
139. Valente, L.; & Nishikura, K. (2005). ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Progress in Nucleic Acid Research and Molecular Biology, 79, 299-338.
140. Nishikura, K. (2006). Editor meets silencer: crosstalk between RNA editing and RNA interference. Nature Review Molecular Cell Biology, 7(12), 919-931.
141. Paz, N.; Levanon, E. Y.; Amariglio, N.; Heimberger, A. B.; Ram, Z.; Constantini, S.; et al. (2007). Altered adenosine-to-inosine RNA editing in human cancer. Genome Research, 17(11), 1586-1595.
142. Maas, S.; Patt, S.; Schrey, M.; & Rich, A. (2001). Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proceeding National Academy Science U S A, 98(25), 14687-14692.
143. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine, 364(26), 2507-2516.
144. Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.; et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711-723.
145. Robert, C.; Thomas, L.; Bondarenko, I.; O'Day, S.; M, D. J.; Garbe, C.; et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364(26), 2517-2526.
146. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; et al. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England Journal of Medicine, 363(9), 809-819.
147. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949-954.
148. Melnikova, V. O.; Dobroff, A. S.; Zigler, M.; Villares, G. J.; Braeuer, R. R.; Wang, H.; et al. (2010). CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS One, 5(8), e12452.
149. Rudolph, D.; Tafuri, A.; Gass, P.; Hammerling, G. J.; Arnold, B.; & Schutz, G. (1998). Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. Proceeding National Academy Science U S A, 95(8), 4481-4486.
150. Yang, E.; Boire, A.; Agarwal, A.; Nguyen, N.; O'Callaghan, K.; Tu, P.; et al. (2009). Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Research, 69(15), 6223-6231.
151. Becker, R. C.; Moliterno, D. J.; Jennings, L. K.; Pieper, K. S.; Pei, J.; Niederman, A.; et al. (2009). Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet, 373(9667), 919-928.
152. Mills, L.; Tellez, C.; Huang, S.; Baker, C.; McCarty, M.; Green, L.; et al. (2002). Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Research, 62(17), 5106-5114.
153. Huang, S.; Mills, L.; Mian, B.; Tellez, C.; McCarty, M.; Yang, X. D.; et al. (2002). Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. The American Journal of Pathology, 161(1), 125-134.